Compare Bristol-Myers Squibb Co (BMY) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.48. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | EMLC | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Fixed Income |
52-Week High | $62.37 | $26.59 |
52-Week Low | $42.60 | $24.83 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EMLC trades at $25.39, down 0.63% over 24 hours, with technical indicators signaling a bearish trend. The ETF maintains a consistent dividend payout, with recent distributions of $0.14 per share. News highlights focus on emerging market debt opportunities amid shifting global volatility, though short interest has risen significantly, indicating investor caution.
Outlook remains mixed; EMLC offers attractive yield above Treasuries but faces currency risk and capital erosion concerns. Key risks include Fed policy shifts and emerging market volatility. Institutional demand is growing, yet high short interest suggests skepticism about sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
